Risperidon Tedavisi ile Kombinasyon Kullanımda Metilfenidat Tedavisinin Kesilmesine Bağlı Gelişen Akut Distonik Reaksiyon: Bir Olgu Sunumu

Year 2024, Volume: 77 Issue: 2, 222 - 226, 12.08.2024

Rahime Duygu Temeltürk

https://doi.org/10.4274/atfm.galenos.2024.80148

Abstract

Project Number

-

Acute Dystonic Reaction Following Methylphenidate Discontinuation During Combination Therapy with Risperidone: A Case Study

Abstract

Attention deficit hyperactivity disorder (ADHD), a prevalent neurodevelopmental disorder, is characterized by attention deficit, hyperactivity, and impulsivity. It frequently accompanies psychiatric disorders, such as oppositional-defiant disorder, anxiety, and mood disorders in children. Current studies indicate a rising use of atypical antipsychotics in conjunction with psychostimulants to treat ADHD and co-occurring disorders. However, the combination therapy may heighten the risk of adverse effects due to drug-drug interactions. One of these side effects is acute dystonic reaction
(ADR), an extrapyramidal symptom characterized by involuntary muscle contractions, particularly in the head and neck region. In this case report, a 6-year-old male patient with ADHD who was initially treated with risperidone and later started on methylphenidate is presented. After discontinuing methylphenidate, the child developed ADR, involuntary contractions in his face and neck. The abrupt cessation of methylphenidate in combination therapy with risperidone resulted in the occurrence of dystonia as an extrapyramidal system side effect. Symptomatic improvement was observed with the biperiden treatment. Pharmacodynamic interactions between methylphenidate and risperidone, particularly involving dopamine pathways, were implicated in the development of ADR. This case report emphasizes the importance of recognizing and managing potential side effects, such as dystonia, when altering combinations of psychostimulant and antipsychotic medications. It also highlights the need for cautious dose adjustments and gradual tapering of medications to mitigate the risk of movement disorders. Additionally, the case underscores the significance of considering individual risk factors, medical history, and genetic predispositions in treatment decision-making.

Keywords

Acute dystonic reaction , attention-deficit hyperactivity disorder , child , methylphenidate , risperidone

Ethical Statement

Informed consent was obtained from the child and his parents.

Supporting Institution

-

Project Number

-

Thanks

-

References

• 1. Köroğlu E. Ruhsal bozuklukların tanısal ve sayımsal el kitabı. Beşinci Baskı (DSM-5), Tanı Ölçütleri Başvuru El kitabı. Ankara: Hekimler Yayın Birliği; 2013:129-131.
• 2. Inci SB, Ipci M, Akyol Ardıç U, et al. Psychiatric comorbidity and demographic characteristics of 1,000 children and adolescents with ADHD in Turkey. J Atten Disord. 2019;23:1356-1367.
• 3. Benjamin E, Salek S. Stimulant-atypical antipsychotic interaction and acute dystonia. J Am Acad Child Adolesc Psychiatry. 2005;6:510-512.
• 4. Guler G, Yildirim V, Kutuk MO, et al. Dystonia in an adolescent on risperidone following the discontinuation of methylphenidate: a case report. Clin Psychopharmacol Neurosci. 2015;13:115-117.
• 5. Doğan Y, Bilaç Ö, Kavurma C. Metilfenidat tedavisinin kesilmesine bağlı gelişen akut distoni: Bir olgu. Anadolu Psikiyatr Derg. 2016;17(Özel Sayı 4):46.
• 6. Mehta SH, Morgan JC, Sethi KD. Drug-induced movement disorders. Neurol Clin. 2015;33:153-174.
• 7. Köse S, Özbaran B, Yazgan Y, et al. The psychometric properties of turkish version of autism spectrum screening questionnaire in children aged 6-18 years. Turk Psikiyatri Derg. 2017;28:268-277.
• 8. Keshen A, Carandang C. Acute dystonic reaction in an adolescent on risperidone when a concomitant stimulant medication is discontinued. J Child Adolesc Psychopharmacol. 2007;17:867-870.
• 9. Grau-López L, Daigre C, Mercado N, et al. Dystonia in methylphenidate withdrawal: A case report. J Addict Med. 2017;11:154-156.
• 10. McLaren JL, Cauble S, Barnett RJ. Aripiprazole induced acute dystonia after discontinuation of a stimulant medication. J Clin Psychopharmacol. 2013;49:58-60.
• 12. Yilmaz AE, Donmez A, Orun E, et al. Methylphenidate-induced acute orofacial and extremity dyskinesia. J Child Neurol. 2013;28:781-783.
• 13. Tekin U, Soyata AZ, Oflaz S. Acute focal dystonic reaction after acute methylphenidate treatment in an adolescent patient. J Clin Psychopharmacol. 2015;35:209-211.
• 14. Ding Y, Fowler JS, Volkow ND, et al. Pharmacokinetics and in vivo specificity of [11C] dl‐threo‐methylphenidate for the presynaptic dopaminergic neuron. Synapse. 1994;18:152-160.
• 15. Rusyniak DE. Neurologic manifestations of chronic methamphetamine abuse. Psychiatr Clin Nort Am. 2013;36:261-275.
• 16. Lundh H, Tunving K. An extrapyramidal choreiform syndrome caused by amphetamine addiction. J Neurol Neurosurg Psychiatry. 1981;44:728-730.
• 17. Stämpfli D, Weiler S, Burden AM. Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance. Eur Child Adolesc Psychiatry. 2021;30:1047-1058.
• 18. Park MH, Park EH. Synaptic concentration of dopamine in rat striatal slices in relationship to [3H] raclopride binding to the dopamine D2 receptor. Arch Pharm Res. 2000;23:360-366.
• 19. Rodnitzky RL, Groth CL. Movement disorder emergencies. Emerg Neurol. 2021;279-303.
• 20. Levy F, Wimalaweera S, Moul C, et al. Dopamine receptors and the pharmacogenetics of side-effects of stimulant treatment for attentiondeficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol. 2013;23:423-425.
• 21. Soria-Chacartegui P, Villapalos-García G, Zubiaur P, et al. Genetic polymorphisms associated with the pharmacokinetics, pharmacodynamics and adverse effects of olanzapine, aripiprazole and risperidone. Front Pharmacol. 2021;12:711940.
• 22. Tarrant N, Roy M, Deb S, et al. The effectiveness of methylphenidate in the management of Attention Deficit Hyperactivity Disorder (ADHD) in people with intellectual disabilities: A systematic review. Res Dev Disabil. 2018;83:217-232.
• 23. Reichow B, Volkmar FR, Bloch MH. Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/ hyperactivity disorder in children with pervasive developmental disorders. J Autism Dev Disord. 2013;43:2435-2441.
• 24. Mohamoud M, Chen Q, Croteau D, et al. Acute hyperkinetic movement disorders as a multifactorial pharmacodynamic drug interaction between methylphenidate and risperidone in children and adolescents. J Clin Psychopharmacol. 2022;42:238-246.